| # | Company | Location | Employees | Total Funding | Last Round | Last Funded |
|---|---|---|---|---|---|---|
| 1 |
Juvena Therapeutics
Juvena Therapeutics develops tissue-restorative biologics to address chronic mus…
|
Palo Alto | 11 - 50 | $113.2M | Series B | 2026-01-12 |
| 2 |
Parabilis Medicines
Parabilis Medicines is a Grupo Bugio is a biopharmaceutical firm that specialize…
|
Cambridge | 101 - 250 | $835.3M | Series F | 2026-01-08 |
| 3 |
Ventyx Biosciences
Ventyx is a biopharmaceutical company focused on advancing oral therapies for pa…
|
San Diego | 101 - 250 | $468.6M | Post Ipo Equity | 2024-09-23 |
| 4 |
BioAge Labs
BioAge Labs is a clinical-stage biotechnology company that develops therapeutics…
|
Richmond | 51 - 100 | $408.9M | Post Ipo Equity | 2026-01-21 |
| 5 |
Diagonal Therapeutics
Diagonal Therapeutics is a biotechnology startup that develops targeted therapie…
|
Watertown | 11 - 50 | $253.0M | Series B | 2026-01-08 |
| 6 |
BrightInsight
BrightInsight offers a global regulated digital health platform for biopharma an…
|
Sunnyvale | 101 - 250 | $179.0M | Series Unknown | 2026-01-20 |
| 7 |
Metsera
Metsera is a clinical-stage biotech firm developing oral & injectable hormone th…
|
New York | 51 - 100 | $505.0M | Series B | 2024-11-13 |
| 8 |
Caris Life Sciences
Caris Life Sciences develops molecular profiling and AI-driven technologies to s…
|
Irving | 1K - 5K | $1.9B | Private Equity | 2025-04-07 |
| 9 |
Precede Biosciences
Precede Biosciences is a biotechnology company that provides a blood-based appro…
|
Boston | 11 - 50 | $140.5M | Series B | 2026-01-12 |
| 10 |
FibroBiologics
FibroBiologics is a regenerative medicine company developing an innovative solut…
|
Houston | 11 - 50 | $145.2M | Post Ipo Equity | 2026-03-31 |
| 11 |
Tessera Therapeutics
Tessera Therapeutics is a biotechnology company pioneering Gene Writing™ to driv…
|
Cambridge | 251 - 500 | $773.1M | Grant | 2026-03-23 |
| 12 |
Aeovian Pharmaceuticals
Aeovian Pharmaceuticals aims to discover, develop, and commercialize therapeutic…
|
San Francisco | 1 - 10 | $142.0M | Series B | 2025-12-16 |
| 13 |
Curi Bio
Curi Bio integrates human stem cells, systems, and AI-enabled data analytics for…
|
Seattle | 11 - 50 | $30.4M | Series B | 2025-12-02 |
| 14 |
Genelux
Genelux is a biopharmaceutical company that develops diagnostic and therapeutic …
|
Westlake Village | 11 - 50 | $129.5M | Post Ipo Equity | 2026-01-09 |
| 15 |
BlossomHill Therapeutics
BlossomHill Therapeutics is a biopharmaceutical company focusing on oncology and…
|
San Diego | 11 - 50 | $257.0M | Series B | 2025-12-10 |
| 16 |
CAMP4 Therapeutics
CAMP4 Therapeutics is a biotechnology company that uses RNA to restore healthy g…
|
Cambridge | 11 - 50 | $270.0M | Post Ipo Equity | 2025-12-18 |
| 17 |
Roivant Sciences
Roivant Sciences is a biopharmaceutical company focused on the development of me…
|
New York | 501 - 1K | $2.5B | Post Ipo Equity | 2023-02-02 |
| 18 |
Oxford Nanopore Technologies
Oxford Nanopore Technologies is a biotechnology company that develops and commer…
|
Oxford | 1K - 5K | $1.6B | Post Ipo Equity | 2024-08-01 |
| 19 |
Cartography Biosciences
Cartography is an oncology company that develops cancer immunotherapies that tar…
|
South San Francisco | 11 - 50 | $124.0M | Series B | 2025-10-02 |
| 20 |
SciNeuro
SciNeuro is a clinical-stage biotechnology company focused on developing groundb…
|
Rockville | 11 - 50 | $158.0M | Series Unknown | 2025-12-04 |
| 21 |
Day One Biopharmaceuticals
Day One Biopharmaceuticals develops targeted therapies to treat people with life…
|
South San Francisco | 101 - 250 | $687.5M | Post Ipo Equity | 2024-07-30 |
| 22 |
NRG Therapeutics
NRG Therapeutics is a drug discovery company focussed on therapeutic approaches …
|
Cambridge | 11 - 50 | $97.3M | Series B | 2025-09-08 |
| 23 |
Ember LifeSciences
Ember LifeSciences is a healthcare technology company that develops cold chain s…
|
Los Angeles | 11 - 50 | $75.9M | Series A | 2025-12-16 |
| 24 |
Canton Strategic Holdings
Canton Strategic Holdings drives institutional blockchain adoption via the Canto…
|
Chester | 11 - 50 | $618.5M | Post Ipo Equity | 2026-01-20 |
| 25 |
Sanegene Bio
Sanegene Bio develops an RNAi drug discovery platform designed for unmet clinica…
|
Woburn | 51 - 100 | $240.0M | Series B | 2025-12-08 |
| 26 |
Zenas BioPharma
Zenas BioPharma is a biopharmaceutical company that focuses on developing immune…
|
Waltham | 101 - 250 | $713.0M | Post Ipo Debt | 2026-03-26 |
| 27 |
Alloy Therapeutics
Alloy Therapeutics is a biotech company that makes medicine by democratizing acc…
|
Waltham | 11 - 50 | $128.2M | Series D | 2022-10-03 |
| 28 |
ErVimmune
ErVimmune develops cancer vaccines and T cell therapies targeting cold tumors us…
|
Lyon | 11 - 50 | $27.7M | Series A | 2026-01-21 |
| 29 |
Vivasure Medical
Vivasure Medical is a medical technology company that develops implantable devic…
|
Galway | 11 - 50 | $98.9M | Series D | 2023-03-13 |
| 30 |
LB Pharmaceuticals
LB Pharmaceuticals specializes in developing LB-102 (n-Methyl amisulpride) as a …
|
New York | 11 - 50 | $233.2M | Post Ipo Equity | 2026-02-05 |
| 31 |
Liberation Bioindustries
Liberation Bioindustries is a biotech firm that develops an industrial biotechno…
|
New York | 11 - 50 | $182.1M | Series Unknown | 2025-12-09 |
| 32 |
Triana Biomedicines
Triana Biomedicines is a developer of a molecular glue discovery platform to reg…
|
Lexington | 11 - 50 | $280.8M | Series B | 2025-12-03 |
| 33 |
Nabla Bio
Nabla Bio is an autoverse platform of proprietary biologically informed machine …
|
Cambridge | 11 - 50 | $37.4M | Series A | 2024-05-14 |
| 34 |
Medicus Pharma
Medicus Pharma is an biotechnology research firm that accelerates life sciences …
|
Toronto | 11 - 50 | $22.4M | Post Ipo Equity | 2025-12-05 |
| 35 |
MapLight Therapeutics
MapLight Therapeutics is a biopharma company that offers a platform designed to …
|
Palo Alto | 51 - 100 | $640.6M | Series D | 2025-07-28 |
| 36 |
Caldera Therapeutics
Caldera Therapeutics is a biotech company engaged in the development of bispecif…
|
Cambridge | 1 - 10 | $112.5M | Series A | 2026-01-14 |
| 37 |
Altos Labs
Altos Labs focuses on cellular rejuvenation programming to restore cell health a…
|
San Francisco | 251 - 500 | $3.0B | Series A | 2021-09-06 |
| 38 |
BIOMAKERS
BIOMAKERS is a biotechnology research company that offers molecular testing and …
|
Recoleta | 101 - 250 | $10.4M | Series A | 2026-01-12 |
| 39 |
ARS Pharmaceuticals
ARS Pharmaceuticals is a stealth pharmaceutical company that specializes in deve…
|
San Diego | 101 - 250 | $175.0M | Post Ipo Debt | 2025-09-29 |
| 40 |
3T Biosciences
3T Biosciences is an immunotherapy company that develops next-generation therapi…
|
Menlo Park | 11 - 50 | $52.0M | Series A | 2022-08-25 |
| 41 |
Absci
Absci is the drug & target discovery company harnessing deep learning AI & synth…
|
Vancouver | 101 - 250 | $394.3M | Post Ipo Equity | 2025-07-24 |
| 42 |
Asklepios BioPharmaceutical
Asklepios BioPharmaceutical is a biotechnology company developing adeno-associat…
|
Chapel Hill | 501 - 1K | $241.8M | Grant | 2020-09-02 |
| 43 |
Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops, manufac…
|
Foster City | c 10001 max | $4.4B | Post Ipo Debt | 2024-11-13 |
| 44 |
Psivant Therapeutics
Psivant Therapeutics is a biotechnology company that offers drug design, biology…
|
Watertown | 11 - 50 | $47.5M | Series A | 2025-12-10 |
| 45 |
Novoron Bioscience
Biotechnology company developing pharmaceutical therapies for nerve regeneration…
|
San Diego | 11 - 50 | $18.7M | Grant | 2026-01-06 |
| 46 |
Nawah Scientific
Nawah is a core hub of advanced research facilites offering online and on demand…
|
Cairo | 51 - 100 | $35.3M | Debt Financing | 2025-12-15 |
| 47 |
Coya Therapeutics
Coya Therapeutics is a T Reg platform company addressing neurodegenerative, auto…
|
Houston | 1 - 10 | $95.9M | Post Ipo Equity | 2026-01-30 |
| 48 |
NRx Pharmaceuticals
NRx Pharmaceuticals is a pharmaceutical company developing therapeutics for the …
|
Wilmington | 11 - 50 | $161.3M | Post Ipo Equity | 2025-09-02 |
| 49 |
Retro Biosciences
Retro Biosciences focuses on cellular reprogramming, autophagy, and plasma-inspi…
|
Redwood City | 51 - 100 | $180.0M | Angel | 2022-04-06 |
| 50 |
Kardigan
Kardigan develops personalized medicines using AI and data to target and treat t…
|
South San Francisco | 51 - 100 | $554.0M | Series B | 2025-10-14 |